WINTON GROUP Ltd decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 23.2% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 28,205 shares of the biopharmaceutical company’s stock after selling 8,506 shares during the quarter. WINTON GROUP Ltd’s holdings in Pfizer were worth $1,023,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of the company. Laurel Wealth Advisors Inc. grew its stake in shares of Pfizer by 9.5% during the 2nd quarter. Laurel Wealth Advisors Inc. now owns 65,964 shares of the biopharmaceutical company’s stock worth $2,393,000 after acquiring an additional 5,718 shares during the period. Nomura Holdings Inc. boosted its stake in Pfizer by 123.5% in the 2nd quarter. Nomura Holdings Inc. now owns 541,074 shares of the biopharmaceutical company’s stock worth $19,630,000 after purchasing an additional 299,022 shares during the period. M Holdings Securities Inc. boosted its stake in Pfizer by 11.9% in the 2nd quarter. M Holdings Securities Inc. now owns 28,495 shares of the biopharmaceutical company’s stock worth $1,034,000 after purchasing an additional 3,031 shares during the period. Carnegie Capital Asset Management LLC boosted its stake in Pfizer by 6.8% in the 2nd quarter. Carnegie Capital Asset Management LLC now owns 122,007 shares of the biopharmaceutical company’s stock worth $4,967,000 after purchasing an additional 7,778 shares during the period. Finally, Amussen Hunsaker Associates LLC boosted its stake in Pfizer by 21.3% in the 2nd quarter. Amussen Hunsaker Associates LLC now owns 10,746 shares of the biopharmaceutical company’s stock worth $390,000 after purchasing an additional 1,886 shares during the period. Institutional investors own 69.42% of the company’s stock.
In other Pfizer news, major shareholder Pfizer Inc purchased 55,556 shares of the stock in a transaction on Monday, October 15th. The shares were purchased at an average price of $18.00 per share, with a total value of $1,000,008.00. Following the acquisition, the insider now directly owns 21,976,484 shares in the company, valued at approximately $395,576,712. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.06% of the company’s stock.
Several research analysts have commented on PFE shares. Cantor Fitzgerald set a $45.00 target price on Pfizer and gave the stock a “buy” rating in a research note on Thursday, October 4th. Morgan Stanley set a $45.00 target price on Pfizer and gave the stock a “buy” rating in a research note on Wednesday, August 29th. Goldman Sachs Group restated a “neutral” rating and issued a $45.00 target price on shares of Pfizer in a research note on Tuesday, October 30th. Independent Research set a $48.00 target price on Pfizer and gave the stock a “neutral” rating in a research note on Thursday, October 4th. Finally, Credit Suisse Group set a $40.00 target price on Pfizer and gave the stock a “hold” rating in a research note on Thursday, September 6th. Two equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and nine have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $43.27.
NYSE:PFE opened at $43.92 on Friday. Pfizer Inc. has a twelve month low of $33.20 and a twelve month high of $46.47. The stock has a market capitalization of $267.76 billion, a price-to-earnings ratio of 16.57, a price-to-earnings-growth ratio of 2.24 and a beta of 0.88. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.15 and a current ratio of 1.43.
Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 30th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.75 by $0.03. Pfizer had a return on equity of 25.26% and a net margin of 44.63%. The firm had revenue of $13.30 billion for the quarter, compared to analysts’ expectations of $13.53 billion. During the same quarter last year, the firm posted $0.67 EPS. The company’s revenue was up 1.0% compared to the same quarter last year. As a group, research analysts expect that Pfizer Inc. will post 3 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Monday, December 3rd. Shareholders of record on Friday, November 9th were issued a $0.34 dividend. The ex-dividend date of this dividend was Thursday, November 8th. This represents a $1.36 annualized dividend and a dividend yield of 3.10%. Pfizer’s payout ratio is currently 51.32%.
COPYRIGHT VIOLATION WARNING: “WINTON GROUP Ltd Cuts Stake in Pfizer Inc. (PFE)” was reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/12/08/winton-group-ltd-cuts-stake-in-pfizer-inc-pfe.html.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Featured Story: Why is Cost of Capital Important?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.